
OpGen OPGN
Quarterly report 2025-Q3
added 11-19-2025
OpGen General and Administrative Expenses 2011-2026 | OPGN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.54 M | 8.08 M | 8.88 M | 9.94 M | 8.8 M | 6.25 M | 7.07 M | 6.69 M | 6.6 M | 5.83 M | 2.31 M | 2.76 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.94 M | 2.31 M | 6.48 M |
Quarterly General and Administrative Expenses OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 702 K | 595 K | 513 K | - | 769 K | 1.57 M | 1.68 M | - | 2.03 M | 2.43 M | 2.42 M | - | 2.02 M | 2.13 M | 2.63 M | - | 2.09 M | 2.69 M | 2.66 M | - | 2.36 M | 2.49 M | 1.7 M | - | 1.56 M | 1.59 M | 1.75 M | - | 1.74 M | 1.83 M | 1.79 M | - | 1.6 M | 1.75 M | 1.97 M | - | 1.64 M | 1.78 M | 1.54 M | - | 1.61 M | 1.42 M | 659 K | - | 555 K | 523 K | 555 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 M | 513 K | 1.65 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 114.84 | -0.55 % | $ 34.9 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 16.3 | 0.62 % | $ 175 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
80.5 M | $ 15.36 | 1.92 % | $ 1.99 B | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 27.2 | 0.33 % | $ 20 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
CareDx, Inc
CDNA
|
108 M | $ 17.82 | -2.68 % | $ 950 M | ||
|
Anixa Biosciences
ANIX
|
6.63 M | $ 2.59 | 1.57 % | $ 84.1 K | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
35.2 M | $ 1.15 | -4.17 % | $ 6.26 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 168.22 | -3.26 % | $ 8.34 B | ||
|
Castle Biosciences
CSTL
|
200 M | $ 24.73 | -0.44 % | $ 687 M | ||
|
Celcuity
CELC
|
27.2 M | $ 114.22 | 1.41 % | $ 5.34 B | ||
|
Danaher Corporation
DHR
|
8.24 B | $ 192.12 | 0.53 % | $ 137 B | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
1.29 B | $ 63.21 | 1.59 % | $ 24.7 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 198.96 | 0.91 % | $ 22.1 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 16.42 | -2.38 % | $ 496 M | ||
|
Guardant Health
GH
|
211 M | $ 89.66 | -4.44 % | $ 11.2 B | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 109.62 | -4.0 % | $ 9.04 B | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 1.97 | 0.63 % | $ 8.72 M | ||
|
Illumina
ILMN
|
1.09 B | $ 127.74 | 0.28 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
2 B | $ 170.72 | -1.47 % | $ 29.3 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 274.46 | 0.27 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 75.89 | -0.28 % | $ 5.12 B | ||
|
Medpace Holdings
MEDP
|
198 M | $ 496.0 | -0.47 % | $ 14.3 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
998 M | $ 1 266.63 | 0.53 % | $ 26.1 B | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.67 | -1.68 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
3.72 M | $ 4.74 | 1.07 % | $ 3.73 M | ||
|
NeoGenomics
NEO
|
273 M | $ 8.02 | 0.25 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.56 | 1.59 % | $ 2.07 B | ||
|
National Research Corporation
NRC
|
54.8 M | $ 17.33 | 0.99 % | $ 388 M |